This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Analyst Blog: Archive
Here's Why Investors Should Hold Ensign Group (ENSG) Stock Now
by Zacks Equity Research
Ensign Group (ENSG) remains well-poised for growth on the back of a growing revenue base, continuous pursuit of acquisitions and commendable financial position.
NVONegative Net Change HUMNegative Net Change CHEPositive Net Change ENSGNegative Net Change
medical
Aflac (AFL) Adds Beneficiary Services to Product Portfolio
by Zacks Equity Research
Aflac (AFL) takes the help of Iris to integrate the Beneficiary Companion service within its life, absence and disability product offerings to ease survivors in settling final affairs post the death of a loved one.
CNONegative Net Change AFLPositive Net Change EIGNegative Net Change GSHDPositive Net Change
insurance
Cambium (CMBM) Unveils Robust Wi-Fi 6/6E Outdoor Solution
by Zacks Equity Research
Cambium (CMBM) launched Wi-Fi 6/6E Tri-Band outdoor Solution to establish and ensure fast and reliable connectivity in outdoor and hostile environments.
SPLKPositive Net Change ANETNegative Net Change VIAVNegative Net Change CMBMPositive Net Change
communications tech-stocks
Abbott's (ABT) Epic Max Tissue Valve Receives FDA Approval
by Zacks Equity Research
Abbott's (ABT) Epic Max design optimizes patient blood flow and has a low profile that makes future cardiac interventions simpler.
ABTPositive Net Change HOLXPositive Net Change HSICNegative Net Change AVNSNegative Net Change
medical medical-devices
ArcelorMittal (MT), Nippon Steel JV Secures Loan From Japan Banks
by Zacks Equity Research
AMNS Luxembourg, the parent company of ArcelorMittal's (MT) steelmaking joint venture with Nippon Steel India, takes $5 billion loan from Japan-based banks to fund capacity expansion projects in India.
STLDNegative Net Change MTNegative Net Change ZEUSNegative Net Change LINPositive Net Change
basic-materials
Scynexis (SCYX) Inks Antifungal Drug Deal With GSK
by Zacks Equity Research
Scynexis (SCYX) enters an exclusive license agreement with GSK to commercialize Brexafemme (ibrexafungerp), an antifungal tablet. GSK will also continue to develop ibrexafungerp for treating invasive candidiasis.
GSKNegative Net Change NVONegative Net Change SCYXPositive Net Change JSPRNegative Net Change
biotechnology medical vaccines
Stratasys (SSYS) to Make H350 3D Printers for Gotz Maschinenbau
by Zacks Equity Research
Stratasys (SSYS) receives order for the production of four of its high-speed H350 3D printers from Gotz Maschinenbau.
BIDUNegative Net Change SSYSNegative Net Change FNNegative Net Change ABNBNegative Net Change
tech-stocks
Tractor Supply's (TSCO) Neighbor's Club Program Aids Growth
by Zacks Equity Research
Tractor Supply (TSCO) is benefiting from Neighbor's Club Program's growth. The company is also well-placed with its expansion plan, supported by new Distribution Center.
TSCONegative Net Change DKSPositive Net Change ULTAPositive Net Change BBWNegative Net Change
retail
Airline Stock Roundup: UAL's Environment-Friendly Deal, ALK, HA in Focus
by Maharathi Basu
In line with the approach of reducing carbon emissions, United Airlines (UAL) and Hawaiian Holdings (HA) ink deals.
UALNegative Net Change SAVENegative Net Change
airlines
Here's Why A. O. Smith (AOS) Stock is Up 39.8% in 6 Months
by Zacks Equity Research
A. O. Smith (AOS) is gaining on strength in its North America segment and accretive acquisitions. Handsome rewards to shareholders add to the stock's appeal.
DENegative Net Change AOSNegative Net Change ALGNegative Net Change ALLENegative Net Change
industrial-products
Simulations Plus (SLP) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
Simulations Plus' (SLP) second-quarter performance is likely to gain from the healthy adoption of its solutions across various verticals.
FASTNegative Net Change STZPositive Net Change SLPNegative Net Change GBXPositive Net Change
tech-stocks
Honda (HMC) Recalls Nearly 330,000 Vehicles Over Safety Issues
by Zacks Equity Research
The vehicle recall by Honda (HMC) covers the 2020-2022 Odyssey, 2020-2022 Passport, 2020-2021 Pilot and 2020-2021 Ridgeline.
HMCNegative Net Change WNCNegative Net Change MODNegative Net Change MZDAYPositive Net Change
auto-tires-trucks
3 Reasons to Retain DaVita (DVA) Stock in Your Portfolio
by Zacks Equity Research
Investors remain optimistic about DaVita (DVA) due to the strength in its DaVita Kidney Care.
DVAPositive Net Change HOLXPositive Net Change HSICNegative Net Change AVNSNegative Net Change
medical medical-devices
Marathon (MRO) to Advance Guinea Gas Mega Hub With Chevron
by Zacks Equity Research
Marathon Oil (MRO) affiliate partners with a Chevron company to develop the Equatorial Guinea Regional Gas Mega Hub. This move is expected to have a positive impact on MRO's profits and cash flows.
CVXNegative Net Change MRONegative Net Change CVINegative Net Change PARRPositive Net Change
energy oil-energy
Here's Why You Should Retain MetLife (MET) in Your Portfolio
by Zacks Equity Research
MetLife's (MET) growing partnerships, strong U.S. and Latin America segments, and cost-cutting efforts are aiding its margins.
METPositive Net Change ORIPositive Net Change GSHDPositive Net Change OSCRNegative Net Change
finance insurance
Paramount (PARA) to Adapt Rebecca Serle's One Italian Summer
by Zacks Equity Research
Paramount Global (PARA) owned Paramount Pictures picks up Rebecca Serle's One Italian Summer for adaptation.
NFLXPositive Net Change DISNegative Net Change WBDNegative Net Change PARANegative Net Change
consumer-discretionary internet-content
Here's Why Investors Should Retain MGM Resorts (MGM) Stock
by Zacks Equity Research
MGM Resorts' (MGM) increased focus on international expansion bodes well. However, subdued visitation in Macau is a concern.
MGMNegative Net Change CROXNegative Net Change FUNPositive Net Change HGVPositive Net Change
consumer-discretionary
Avidity (RNA) Down on Update From Neuromuscular Disease Study
by Zacks Equity Research
Avidity Biosciences (RNA) provides an update on its phase I/II study of its lead product candidate AOC 1001 for the treatment of myotonic dystrophy type I. The stock falls about 17%.
RNANegative Net Change ADMANegative Net Change APTXPositive Net Change ANVSNegative Net Change
biotechs
Here's Why You Should Retain Red Robin (RRGB) Stock for Now
by Zacks Equity Research
Red Robin (RRGB) emphasizes cooking technique upgrades and transitioning to a traditional service model to drive growth. However, inflationary pressures are a concern.
RRGBPositive Net Change BLMNNegative Net Change ARCOPositive Net Change
restaurants retail
6 Reasons Why You Should Bet on ICF International (ICFI)
by Zacks Equity Research
ICF International (ICFI) continues to focus on deepening its presence in the core U.S. federal, and state and local government markets, expanding commercial business, and strengthening technology-based offerings.
OMCNegative Net Change ITPositive Net Change ICFINegative Net Change
business-services
Should You Retain EverQuote (EVER) Stock in Your Portfolio?
by Zacks Equity Research
EverQuote (EVER) is poised to benefit from solid performance of automotive and other insurance marketplace verticals and higher consumer traffic.
CNONegative Net Change EVERNegative Net Change ORIPositive Net Change JRVRNegative Net Change
insurance
Here's Why H&R Block (HRB) Stock is a Great Pick Right Now
by Zacks Equity Research
The main drivers of H&R Block's (HRB) post-pandemic performance are digital enablement of business, client addition and retention, and greater use of AI for product improvement.
OMCNegative Net Change HRBNegative Net Change ITPositive Net Change ICFINegative Net Change
business-services
Western Digital (WDC) & Kioxia Launch New 3D Flash Memory
by Zacks Equity Research
Western Digital (WDC) and Kioxia Corporation unveil new 3D flash memory technology with improved performance and reliability.
WDCNegative Net Change PERIPositive Net Change PEGAPositive Net Change ANETNegative Net Change
tech-stocks
BlackBerry (BB) Incurs Loss in Q4, Revenues Decline Y/Y
by Zacks Equity Research
BlackBerry's (BB) fourth-quarter fiscal 2023 revenues are impacted by weakness in Cybersecurity business.
PERIPositive Net Change PEGAPositive Net Change ANETNegative Net Change BBPositive Net Change
tech-stocks
Why You Should Retain Alaska Air (ALK) Stock in Portfolio Now
by Zacks Equity Research
Alaska Air's (ALK) management expects first-quarter 2023 total revenues to increase 29-32% from the first-quarter 2022 actuals.
CPANegative Net Change ALKNegative Net Change GATXNegative Net Change
airlines